Multiple Sclerosis | Current Treatment | EU5 | 2016
The EU5 market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is dynamic and evolving. More than ten key branded DMTs are available, with several launching in the past five years, each delivering a unique balance of benefit, risk, and convenience. New agents, in particular oral DMTs, have meaningfully altered physician preferences and introduced new complexity into an already complicated treatment paradigm. Understanding the many decision points facing EU5 neurologists in the shifting treatment of MS provides, and in five unique countries, important context for developers of marketed and pipeline DMTs.
Related Market Assessment Reports
Report
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)
Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision…
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Treatment Algorithms: Claims Data Analysis – Atopic Dermatitis (Pediatric) (US)
Atopic dermatitis (AD) is a chronic, itchy, inflammatory skin disease often starting in childhood. It is usually treated with topical immunotherapy. Refractory cases may need systemic…
Report
Schizophrenia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Schizophrenia (US)
Schizophrenia is a chronic psychiatric disorder that requires sustained pharmacologic management to reduce psychotic episodes and maintain long-term symptom stability. It is a highly drug-treated…
Report
Uveitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Noninfectious Uveitis–Posterior Segment
Most vision loss from uveitis stems from persistent inflammation in the posterior segment of the eye. While noninfectious anterior uveitis is usually managed effectively with topical steroids,…
